Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of this trial is to investigate the efficacy and safety of pramipexole
(0.125-0.75 mg) orally once daily as compared with placebo for 6 weeks in patients with
primary restless legs syndrome (RLS) and to investigate the reliability of the Japanese
version of the RLS rating scale by the International Restless Legs Syndrome Study Group
(IRLSSG) as a sub-study.